皮下注射醋酸亮丙瑞林在前列腺癌患者中实现低睾酮最低点的有效性。
Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.
作者信息
Pieczonka Christopher M, Twardowski Przemyslaw, Renzulli Joseph, Hafron Jason, Boldt-Houle Deborah M, Atkinson Stuart, Eggener Scott
机构信息
Associated Medical Professionals Syracuse, NY.
Providence Hospital Santa Monica Santa Monica, CA.
出版信息
Rev Urol. 2018;20(2):63-68. doi: 10.3909/riu0798.
Abstract
Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and <3% experienced a microsurge. Achievement and maintenance of low nadir testosterone levels may improve progression-free survival and time to onset of castrate-resistant prostate cancer.
摘要
有证据表明，雄激素剥夺治疗第一年较低的睾酮最低点水平可改善晚期前列腺癌的临床结局。我们评估了皮下注射醋酸亮丙瑞林（1、3、4和6个月剂量）的关键试验，以确定睾酮最低点水平。汇总分析显示，分别有99%、97%和91%的患者睾酮最低点≤20、≤10和≤5 ng/dL（中位数≤3 ng/dL）。在所有可用类别中，88%的患者睾酮最低点≤5 ng/dL，且<3%的患者经历了微小波动。低睾酮最低点水平的实现和维持可能会改善无进展生存期和去势抵抗性前列腺癌的发病时间。
相似文献
1
Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.皮下注射醋酸亮丙瑞林在前列腺癌患者中实现低睾酮最低点的有效性。
Rev Urol. 2018;20(2):63-68. doi: 10.3909/riu0798.
2
A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.一种新的控释、3 个月的醋酸亮丙瑞林制剂可使前列腺癌患者达到并维持去势浓度的睾酮。
Clin Ther. 2019 Mar;41(3):412-425. doi: 10.1016/j.clinthera.2019.01.004. Epub 2019 Feb 8.
3
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.在四项针对晚期前列腺癌患者的开放标签研究中，聚合物递送的皮下注射醋酸亮丙瑞林制剂可达到并维持睾酮的去势浓度。
BJU Int. 2017 Feb;119(2):239-244. doi: 10.1111/bju.13482. Epub 2016 Apr 16.
4
Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.雄激素剥夺治疗的持续时间以及睾酮水平最低点达到20 ng/dL，可预测接受外照射放疗的前列腺癌患者睾酮恢复至去势水平以上。
Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11.
5
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.不同醋酸亮丙瑞林制剂（原位凝胶和微球）延迟给药对睾酮抑制作用的影响：美国临床数据分析。
J Urol. 2021 Feb;205(2):554-560. doi: 10.1097/JU.0000000000001392. Epub 2020 Oct 22.
6
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.复发或局部进展性前列腺癌患者连续雄激素剥夺治疗后的临床结局和睾酮水平：ICELAND 研究的事后分析。
J Urol. 2017 Nov;198(5):1054-1060. doi: 10.1016/j.juro.2017.05.072. Epub 2017 May 25.
7
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.基于血清睾酮水平确定促黄体生成素释放激素激动剂的给药间隔：一项前瞻性研究。
J Urol. 2007 Jun;177(6):2132-5; discussion 2135. doi: 10.1016/j.juro.2007.01.157.
8
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.前列腺癌的新治疗模式：阿巴瑞克起始治疗即刻抑制睾酮，随后使用促黄体生成素释放激素激动剂。
BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16.
9
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.用于治疗晚期前列腺癌的醋酸亮丙瑞林缓释6个月剂型：使睾酮水平降至20 ng/dl以下。
Expert Opin Drug Metab Toxicol. 2015;11(9):1465-74. doi: 10.1517/17425255.2015.1073711.
10
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
引用本文的文献
1
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.雄激素剥夺疗法对晚期前列腺癌患者心血管系统的影响。
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
2
A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy.一项关于睾酮逃逸对接受新辅助雄激素剥夺治疗的前列腺癌患者放疗前前列腺特异性抗原动力学影响的前瞻性研究。
Curr Urol. 2021 Mar;15(1):63-67. doi: 10.1097/CU9.0000000000000008. Epub 2021 Mar 29.
3
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review.当前雄激素受体抑制疗法治疗前列腺癌的现状与展望：全面综述。
Biomolecules. 2021 Mar 25;11(4):492. doi: 10.3390/biom11040492.
4
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy.前列腺癌中的雄激素受体：结构、配体及剪接变体对治疗的影响
Biomedicines. 2020 Oct 15;8(10):422. doi: 10.3390/biomedicines8100422.
5
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.前列腺癌中雄激素受体（AR）及AR变体的治疗靶向作用
Asian J Urol. 2020 Jul;7(3):271-283. doi: 10.1016/j.ajur.2020.03.002. Epub 2020 Mar 7.
本文引用的文献
1
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
2
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.醋酸阿比特龙和泼尼松用于未经化疗的前列腺癌患者：理论依据、证据及临床应用
Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22.
3
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.在四项针对晚期前列腺癌患者的开放标签研究中，聚合物递送的皮下注射醋酸亮丙瑞林制剂可达到并维持睾酮的去势浓度。
BJU Int. 2017 Feb;119(2):239-244. doi: 10.1111/bju.13482. Epub 2016 Apr 16.
4
Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.长期随访后的睾酮最低点可预测接受联合雄激素阻断治疗的前列腺癌患者的预后。
J Urol. 2015 Nov;194(5):1264-70. doi: 10.1016/j.juro.2015.03.120. Epub 2015 Apr 7.
5
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.雄激素剥夺治疗（ADT）第一年的睾酮最低点可预测去势抵抗性进展时间：间歇性与持续性ADT的PR-7试验的二次分析
J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2.
6
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.MR/超声融合引导活检与超声引导活检诊断前列腺癌的比较。
JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.
7
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.醋酸阿比特龙联合醋酸亮丙瑞林对局限性高危前列腺癌患者进行强化雄激素剥夺治疗：一项随机II期新辅助研究的结果
J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.
8
Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.前列腺癌的间歇性雄激素剥夺疗法：将随机对照试验转化为临床实践
Can J Urol. 2014 Apr;21(2 Supp 1):28-36.
9
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.EAU 前列腺癌指南。第 1 部分：筛查、诊断和以治愈为目的的局部治疗——2013 年更新。
Eur Urol. 2014 Jan;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.
10
Experience with degarelix in the treatment of prostate cancer.degarelix 治疗前列腺癌的经验。
Ther Adv Urol. 2013 Feb;5(1):11-24. doi: 10.1177/1756287212461048.
Zotero 插件